TY - JOUR T1 - Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm DO - 10.1136/ejhpharm-2021-002896 SP - ejhpharm-2021-002896 AU - Sandra Rotea-Salvo AU - Alejandro Martínez-Pradeda AU - Carla Fernández-Oliveira AU - Victor Giménez-Arufe AU - Vanesa Balboa-Barreiro AU - Luis Margusino-Framiñán AU - Álvaro Mena-De-Cea AU - Pilar Vázquez-Rodríguez AU - Ángeles Castro-Iglesias AU - Soledad López-Calvo AU - Isabel Martín-Herranz AU - Enrique Míguez-Rey AU - Purificación Cid-Silva Y1 - 2021/10/14 UR - http://ejhp.bmj.com/content/early/2021/10/14/ejhpharm-2021-002896.abstract N2 - Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients.Objectives This study evaluated modifications in the renal safety profile in a large real‐world cohort of patients who had received EVG/c/FTC/TAF or DTG/ABC/3TC.Methods A retrospective observational study of HIV-infected patients who received EVG/c/FTC/TAF or DTG/ABC/3TC between March 2015 and June 2019 at a reference hospital in north-western Spain was conducted. Epidemiological, clinical, immunovirological data and information regarding antiretroviral therapy were recorded. The statistical differences between treatments were calculated.Results A total of 457 patients were evaluated, 266 using EVG/c/FTC/TAF and 191 using DTG/ABC/3TC. Up to week 120, serum creatinine improved in both study groups among experienced patients (EVG/c/FTC/TAF 1.01±0.24 vs 0.91±0.19, p<0.001; DTG/ABC/3TC 1.08±0.24 vs 1.02±0.31, p<0.001), while in naïve patients serum creatinine remained stable compared with baseline. Statistically significant differences were found in serum creatinine when comparing both treatments at week 48 in experienced (0.94±0.21 vs 1.09±0.28, p<0.001) and naïve patients (0.89±0.16 vs 1.06±0.20, p=0.001), and among experienced patients at week 120 (0.91±0.19 vs 1.02±0.31, p=0.015) for the EVG/c/FTC/TAF and DTG/ABC/3TC groups, respectively. During the follow-up, 39 patients in EVG/c/FTC/TAF and 33 in DTG/ABC/3TC (p=0.449) discontinued treatment. The main reason for stopping treatment was adverse events, which were similar in both groups.Conclusions During the follow-up, patients experienced changes that were not clinically relevant in both treatment groups. Differences in renal events were not found.Data are available upon reasonable request. ER -